Long‐term serological outcome of infants who received frozen–thawed milk from human T‐lymphotropic virus type‐I positive mothers

Ando, Yoshiya; Ekuni, Yutaka; Matsumoto, Yoshinari; Nakano, Shiro; Saito, Kensuke; Kakimoto, Kazuhiro; Tanigawa, Takuo; Kawa, Motohiro; Toyama, Takenori

doi:10.1111/j.1447-0756.2004.00227.x

Cited by 37 publications

(27 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, fresh frozen plasma from seropositive donors did not transmit HTLV-I (Okochi et al, 1984). Hence, if living cells can be eliminated by freeze and thawing, then feeding the mother's breast milk to infants will not increase viral transmission (Ando et al, 2004). These findings clearly show that physiological transmission requires live HTLV-I-infected cells.…”

Section: Transmission Of Htlv-imentioning

confidence: 78%

Natural history of adult T-cell leukemia/lymphoma and approaches to therapy

2005

View full text Add to dashboard Cite

After cell-to-cell transmission, HTLV-I increases its viral genome by de novo infection and proliferation of infected cells. Proliferation of infected cells is clonal and persistent in vivo. During the carrier state, infected cells are selected in vivo by the host's immune system, the genetic and epigenetic environment of proviral integration sites, and other factors. In leukemic cells, tax gene expression is frequently impaired by genetic and epigenetic mechanisms. Such loss of Tax expression enables ATL cells to escape the host immune system. On the other hand, ATL cells acquire the ability to proliferate without Tax by intracellular genetic and epigenetic changes. Despite advances in support and the development of novel treatment agents, the prognosis for ATLL remains poor. A number of therapies, however, do appear to improve prognosis compared to CHOP (VEPA). These include interferon-a plus zidovudine (probably after 1-2 cycles of CHOP), intensive chemotherapy as in LSG-15 with G-CSF support and Allo-SCT (which includes the potential for cure). Emerging novel approaches include HDAC inhibitors, monoclonal antibodies, and proteasome inhibitors. Comparison between different therapeutic approaches is complicated by the range of natural history of ATLL, different recruitments of naı¨ve-to-therapy, refractory or relapsed patients, and variations in the reporting of outcome that frequently excludes difficultto-evaluate patients. Moreover, results from relatively small proof-of-principle studies have not been extended with randomized, controlled trials. As a result, currently, there is no clear evidence to support the value of any particular treatment approach over others. To avoid further unnecessary patient suffering and to identify optimal therapy as rapidly as possible, large randomized, controlled trials encompassing multicenter, international collaborations will be necessary.

show abstract

Section: Transmission Of Htlv-imentioning

confidence: 78%

Natural history of adult T-cell leukemia/lymphoma and approaches to therapy

2005

View full text Add to dashboard Cite

show abstract

“…In either route, HTLV-I-infected cells are essential for transmission. This was supported by the findings that fresh frozen plasma from carriers did not cause transmission [51] and freeze-thawing of breast milk reduced vertical transmission [52]. …”

Section: Introductionmentioning

confidence: 79%

Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL)

Matsuoka

2005

Retrovirology

131

View full text Add to dashboard Cite

The clinical entity of adult T-cell leukemia (ATL) was established around 1977, and human T-cell leukemia virus type 1 (HTLV-I) was subsequently identified in 1980. In the 25 years since the discovery of HTLV-I, HTLV-I infection and its associated diseases have been extensively studied, and many of their aspects have been clarified. However, the detailed mechanism of leukemogenesis remains unsolved yet, and the prognosis of ATL patients still poor because of its resistance to chemotherapy and immunodeficiency. In this review, I highlight the recent progress and remaining enigmas in HTLV-I infection and its associated diseases, especially ATL.

show abstract

“…3 HTLV-I is transmitted intravenously, by sexual contact, or through breast-feeding from mother to child, and epidemiological evidence predicts that ATLL development occurs following childhood infection. 4 ATLL exhibits diverse clinical features: the acute, the subacute or smoldering, the chronic forms and the ATL lymphoma. 5 In the two most aggressive forms (acute leukemia and lymphoma), the tumor syndrome comprises massive lymphadenopathy, hepatosplenomegaly, lytic bone lesions and multiple visceral lesions with skin and lung infiltration.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody

et al. 2007

View full text Add to dashboard Cite

Long‐term serological outcome of infants who received frozen–thawed milk from human T‐lymphotropic virus type‐I positive mothers

Abstract: This study showed that freeze-thaw processing can eliminate the HTLV-I infectivity of mothers' milk, and that HTLV-I carriers can indirectly feed their infants using frozen-thawed mothers' milk as a way to prevent HTLV-I infection.

Cited by 37 publications

References 7 publications

Natural history of adult T-cell leukemia/lymphoma and approaches to therapy

Natural history of adult T-cell leukemia/lymphoma and approaches to therapy

Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL)

Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody

Contact Info

Product

Resources

About